Myeloproliferative Neoplasms

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

MNV-201 has received orphan drug designation from the FDA for use in myelodysplastic syndrome.

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.